Acura Hit With Securities Suit Over Acurox Claims

Law360, New York (September 13, 2010, 7:52 PM EDT) -- A shareholder has filed a putative securities fraud class action against Acura Pharmaceuticals Inc., claiming the drugmaker misrepresented the chances that its flagship painkiller would gain U.S. Food and Drug Administration approval in order to inflate its stock price.

Chris Bang filed suit Friday in the U.S. District Court for the Northern District of Illinois on behalf of anyone who purchased Acura stock during a four-year period from February 2006 to April 2010, alleging the company and certain officers made repeated false or misleading statements concerning...
To view the full article, register now.